End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 19 | Aclaris Therapeutics, Inc. Announces Board Resignations | CI |
Feb. 27 | Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 7.76M | Sales 2025 * | 8.69M | Capitalization | 85.52M |
---|---|---|---|---|---|
Net income 2024 * | -73M | Net income 2025 * | -70M | EV / Sales 2024 * | 1.84 x |
Net cash position 2024 * | 71.24M | Net cash position 2025 * | 157M | EV / Sales 2025 * | -8.28 x |
P/E ratio 2024 * |
-1.23
x | P/E ratio 2025 * |
-1.32
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
Latest transcript on ACLS THER
Managers | Title | Age | Since |
---|---|---|---|
Neal Walker
CEO | Chief Executive Officer | 54 | 12-06-30 |
Kevin Balthaser
DFI | Director of Finance/CFO | - | 16-12-31 |
Ajay Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Schiff
BRD | Director/Board Member | 58 | 17-08-08 |
Maxine Gowen
BRD | Director/Board Member | 66 | 19-07-01 |
Andrew Powell
BRD | Director/Board Member | 66 | 17-01-24 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |